Aparicio-López Verónica, Rueda-Extremera María, Cantero-García María
Universidad Internacional de Valencia, Valencia, Spain.
Faculty of Health Sciences and Education, Universidad a Distancia de Madrid (UDIMA), Collado Villalba, Spain.
J Psychopharmacol. 2025 Apr;39(4):316-327. doi: 10.1177/02698811241277200. Epub 2024 Sep 16.
This review addresses the prevalence of hypersexual behavior in Parkinson's patients and the underlying neurobiological mechanisms, identifying risk and protective factors, comparing incidence among different treatments, and proposing recommendations for management and prevention.
To conduct a review on the relationship between Parkinson's disease and hypersexual behavior as a result of pharmacological treatment.
The search strategy, guided by PRISMA and PICOS criteria, focuses on the correlation between Parkinson's disease and hypersexual behavior due to pharmacological treatment. Utilizing databases like PubMed and Proquest, studies from the last 10 years in English or Spanish were selected, emphasizing clinical trials with Parkinson's patients under treatment. Inaccessible, irrelevant, or mixed-sample studies were excluded. The Cochrane Scale assessed the risk of bias.
Out of 122 records, 103 remained after eliminating duplicates; 48 were reviewed, and ultimately, 6 studies met the inclusion criteria for analysis.
Synthesizing the risk and protective factors linked to hypersexual behavior in Parkinson's patients receiving pharmacological treatment underscores the critical need for early detection and incorporation of these factors into clinical care. The suggested guidelines for managing and preventing hypersexual behavior in these patients carry substantial practical implications.
本综述探讨帕金森病患者中性行为亢进的患病率及其潜在的神经生物学机制,识别风险和保护因素,比较不同治疗方法中的发生率,并提出管理和预防建议。
对帕金森病与药物治疗导致的性行为亢进之间的关系进行综述。
在PRISMA和PICOS标准的指导下,搜索策略聚焦于帕金森病与药物治疗导致的性行为亢进之间的相关性。利用PubMed和Proquest等数据库,选择过去10年以英文或西班牙文发表的研究,重点关注帕金森病患者接受治疗的临床试验。排除无法获取、不相关或混合样本的研究。采用Cochrane量表评估偏倚风险。
在122条记录中,去除重复记录后剩下103条;对48条进行了审查,最终有6项研究符合纳入分析的标准。
综合接受药物治疗的帕金森病患者中与性行为亢进相关的风险和保护因素,凸显了早期检测并将这些因素纳入临床护理的迫切需求。针对这些患者管理和预防性行为亢进的建议指南具有重大实际意义。